Storia in 3 fonti

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

Raccontata da

medpagetoday.com

morningstar.com

benzinga.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo3 g fa

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient…

TRUQAP won FDA approval for PTEN-deficient metastatic prostate cancer with 19% risk reduction—first targeted therapy available. Companion diagnostic approval marks precision medicine maturity: genomic testing bundled with therapy now reshapes oncology development and reimbursement.

originale

medpagetoday.com3 g fa

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Questo articolo non è rilevante per Warptech Tech News — è medico/pharma (approvazione FDA di un farmaco oncologico), non tech/AI/business. Puoi mandarmi un articolo tech-relato da riassumere secondo le regole editoriali?

Timeline cronologica

venerdì 12 giugno 2026·medpagetoday.com
FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting
Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors
sabato 13 giugno 2026·morningstar.com
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive…
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

Confronto fonti

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient…

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Timeline cronologica

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive…

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod - AstraZeneca (

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod - AstraZeneca (